US 12,187,690 B2
Benzothiadiazepine compounds and their use as bile acid modulators
Per-Göran Gillberg, Åsbro (SE); Jan Mattsson, Kullavik (SE); Ingemar Starke, Gothenburg (SE); and Santosh S. Kulkarni, Bangalore (IN)
Assigned to Albireo AB, Gothenburg (SE)
Filed by Albireo AB, Gothenburg (SE)
Filed on Feb. 3, 2023, as Appl. No. 18/164,185.
Application 18/164,185 is a continuation of application No. 17/130,148, filed on Dec. 22, 2020, granted, now 11,603,359.
Application 17/130,148 is a continuation of application No. 16/805,252, filed on Feb. 28, 2020, granted, now 10,941,127, issued on Mar. 9, 2021.
Application 16/805,252 is a continuation of application No. PCT/EP2020/052942, filed on Feb. 6, 2020.
Claims priority of application No. 201911004690 (IN), filed on Feb. 6, 2019; application No. 1950464-6 (SE), filed on Apr. 12, 2019; and application No. 201911049981 (IN), filed on Dec. 4, 2019.
Prior Publication US 2023/0406832 A1, Dec. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 285/36 (2006.01); A61P 1/16 (2006.01)
CPC C07D 285/36 (2013.01) [A61P 1/16 (2018.01)] 20 Claims
 
1. A compound of formula (I-b)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein
R2 is methyl, ethyl, n-propyl or n-butyl;
R3 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, hydroxy, cyano, trifluoromethyl, methoxy, and trifluoromethoxy;
R4 is selected from the group consisting of fluoro, chloro, bromo, hydroxy, cyano, methoxy, ethoxy, methylthio, ethylthio and dimethylamino; and
R5A is selected from the group consisting of hydrogen, halogen, hydroxy, amino and methyl.